Copyright
©The Author(s) 2025.
World J Hepatol. May 27, 2025; 17(5): 106618
Published online May 27, 2025. doi: 10.4254/wjh.v17.i5.106618
Published online May 27, 2025. doi: 10.4254/wjh.v17.i5.106618
Table 1 Magnitude of anti-tuberculosis drug-induced acute liver failure in various published studies
Ref. | Study design | n (diagnosis) | n (AT-DILI) | n (AT-ALF) | Proportion of AT-ALF |
Anand et al[44], 2006 | Observational | 152 (TB) | 22 (13.8%) | 09 | 13% of prospective cohort (6/69) |
Pande et al[22], 1996 | Prospective, case-control | 492 (TB) | 86 | 05 | 5.8% of AT-DILI |
Devarbhavi et al[26], 2013 | Retro-prospective cohort | 269 (AT-DILI) | 269 | 69 | 25.7% of AT-DILI |
Dawra et al[24], 2029 | Retrospective cohort | 141 (TB) | 10 | 01 | 10% of AT-DILI |
Latief et al[23], 2017 | Prospective cohort | 200 (TB) | 16 | 01 | 6.2% of AT-DILI |
Raj Mani et al[13], 2021 | Prospective cohort | 397 (TB) | 38 | 04 | 10.5% of AT-DILI |
Kumar et al[19], 2010 | Retrospective analysis | 1223 (ALF) | - | 70 | 5.7% of ALF |
Wang et al[27], 2020 | Retrospective analysis | 155 (AT-DILI) | 155 | 55 | 35.4% of AT-DILI |
Ichai et al[28], 2010 | Retrospective analysis | 566 (ALF) | - | 14 | 2.47% of ALF |
Mindikoglu et al[29], 2009 | Retrospective analysis | 661 (drug-induced ALF) | - | 50 | 7.5% of drug-induced ALF |
Table 2 Outcomes of patients with anti-tuberculosis drug-induced acute liver failure
Ref. | AT-ALF (n) | Demographic features | ATD-ALF interval | LT, n (%) | Post-LT survival (%) | Mortality (%) |
Ichai et al[28], 2010 | 14 | 04 (28.5%) male, 10 (71.5%) female, median age – 37 years | 3.5 ± 3.1 months | 6 (42.8) | 50 | 28.5 |
Kumar et al[19], 2010 | 70 | 21 (30%) male, 49 (70%) female, mean age 328 years | 30 (7-350) days | None | - | 67.1 |
Idilman et al[11], 2006 | 1 | Female, 19 years | 3 days | 1 (100) | 100 | None |
Mindikoglu et al[29], 2009 | 50 | 32 (64%) female, 18 (36%) male | - | 50 (100) | 82 | 18 |
Bavikatte et al[67], 2017 | 7 | 03 (42.8%) male, 04 (57.2%) female, median age – 32 (5-39) years | 2 months | 7 (100) | 71.4 | 28 |
Huh et al[52], 2017 | 19 | 10 (52.6%) male, 9 (47.4%) female, mean age – 46 years | 61 (40-113) days | 6 (31.5) | 100 | 52.6 |
Li et al[39], 2018 | 1 | Male, 67 years | 77 days | 1 (100) | 0 | 100 |
Martino et al[49], 2018 | 8 | 08 (100%) female, median age – 39 (17-56) years | 21 to 155 days | 8 (100) | 50 | 50 |
Bartoletti et al[63], 2017 | 26 | 14 (54%) male, 12 (46%) female, median age – 38 (25-50) years | - | 26 (100) | 85 | 15 |
Wang et al[27], 2020 | 55 | 34 (61.8%) male, 21 (39.2%) female, mean age 50.3 ± 15.9 years | 51 (7-330 days) | None | - | 9.68 |
Smink et al[65], 2006 | 2 | 01 male and 01 female | 139.5 days | 2 (100) | 2 (100) | None |
Zhu et al[66], 2021 | 1 | Female, 26 years | 3 days | 1 (100) | 100 | None |
Farrell et al[46], 1994 | 2 | 49 years male and 60 years female | 4 months and 6 weeks | 2 (100) | 100 | None |
Barcena et al[47], 2005 | 1 | Male, 39 years | 1 month | 1 (100) | 100 | None |
Pessayre et al[12], 1977 | 6 | 01 (17%) male, 05 (83%) female, mean age – 46 ± 24 years | 7.3 ± 1.8 days | 0 | - | None |
Mitchell et al[48], 1995 | 4 | 01 (25%) male, 03 (75%) female, mean age – 51.75 ± 13.98 | 3.5 ± 2.3 months | 2 (50) | 50 | 50 |
Cillo et al[64], 2005 | 1 | Female, 10 years | 3 months | 1 (100) | 100 | None |
Campos et al[10], 2004 | 1 | Female,16 years | 5 days | 0 | - | None |
- Citation: Kumar R, Kumar A, Kumar S. Acute liver failure from anti-tuberculosis drug-induced liver injury: An update. World J Hepatol 2025; 17(5): 106618
- URL: https://www.wjgnet.com/1948-5182/full/v17/i5/106618.htm
- DOI: https://dx.doi.org/10.4254/wjh.v17.i5.106618